Dr. Maris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
CBCI, 1721 East 19th Ave
Ste 300
Denver, CO 80218Phone+1 720-754-4800Fax+1 720-754-4801- Is this information wrong?
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 2001
Oregon Health & Science UniversityResidency, Internal Medicine, 1995 - 1998
Perelman School of Medicine at the University of PennsylvaniaClass of 1995
Certifications & Licensure
OR State Medical License 1997 - Present
CO State Medical License 2005 - 2025
WY State Medical License 2009 - 2024
NM State Medical License 2013 - 2017
WA State Medical License 1998 - 2006- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib Start of enrollment: 2001 Jul 13
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons, Martha Arellano, Reem Karmali, Gary Schiller, Elizabeth Cull, Camille N Abboud, Connie Batlevi,...> ;Targeted Oncology. 2024 Apr 29
- 9 citationsA Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre Goy, Anas Younes, Suresh Bobba, Adrian M Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Pa...> ;Cancer Research Communications. 2022 Aug 1
- Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJason R. Westin, Michael B. Maris, Caron A. Jacobson, Prapti A. Patel, Nehal Lakhani, Wael A. Harb, Dipti Patel-Donnelly, Kelly McCaul, Carolina Escobar, Barbara Klenc...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 25
- Join now to see all
Abstracts/Posters
- Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled StudyMichael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Michael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...Michael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Grant Support
- Nonmyeloablative Allografting For Hematologic NeoplasiaNational Cancer Institute2001–2005
Professional Memberships
- Member
Hospital Affiliations
Presbyterian/St. Luke's Medical CenterDenver, Colorado
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
